It is very uncertain whether sunitinib changes serious adverse events (Grade 3 or 4) compared with atezolizumab + bevacizumab (targeted agent versus immunotherapy +… (very low certainty).
It is very uncertain whether sunitinib changes progression‐free survival (absolute effect size estimates based on… compared with IMA901 + sunitinib (targeted agent versus tumour vaccine + targeted… (very low certainty).
Sunitinib showed no clear difference in overall survival (absolute effect size estimates based on survival… compared with IMA901 + sunitinib (targeted agent versus tumour vaccine + targeted… (low certainty).
Sunitinib may leads to lower serious adverse events (Grade 3 or 4) compared with IMA901 + sunitinib (targeted agent versus tumour vaccine + targeted… (low certainty).
The review found no eligible studies for this question.
Sunitinib probably leads to lower progression‐free survival (absolute effect size estimates based on… compared with interferon‐α (IFN‐α) (targeted agent versus classic immunotherapy) (moderate certainty).
Sunitinib showed no clear difference in overall survival (absolute effect size estimates based on survival… compared with interferon‐α (IFN‐α) (targeted agent versus classic immunotherapy) (low certainty).
Sunitinib probably leads to higher serious adverse events (Grade 3 or 4)assessed as: CTCAE v3.0 compared with interferon‐α (IFN‐α) (targeted agent versus classic immunotherapy) (moderate certainty).
The review found no eligible studies for this question.
Temsirolimus may leads to lower progression‐free survival (absolute effect size estimates based on… compared with IFN‐α (targeted agent versus classic immunotherapy) (low certainty).
Temsirolimus probably leads to lower overall survival survival (absolute effect size estimates based on… compared with IFN‐α (targeted agent versus classic immunotherapy) (moderate certainty).
Temsirolimus may leads to lower serious adverse events (Grade 3 or 4) compared with IFN‐α (targeted agent versus classic immunotherapy) (low certainty).
It is very uncertain whether sunitinib changes progression‐free survival (absolute effect size estimates based on… compared with atezolizumab (targeted therapy versus immunotherapy) (very low certainty).
It is very uncertain whether sunitinib changes overall survival (absolute effect size estimates based on survival… compared with atezolizumab (targeted therapy versus immunotherapy) (very low certainty).
Sunitinib probably leads to higher serious adverse events (Grade 3 or 4) compared with atezolizumab (targeted therapy versus immunotherapy) (moderate certainty).
Bevacizumab + IFN probably leads to lower progression‐free survival (absolute effect size estimates based on… compared with IFN (+ placebo) (targeted agent + classic immunotherapy versus… (moderate certainty).